Medtronic Neuro Gets Warning Letter, FDA Wants to Meet on Motor Flaws

Devices & Diagnostics Letter
A A
Medtronic’s neuromodulation unit has received an FDA warning letter on allegations the business segment did not handle complaints properly, among other corrective and preventive action (CAPA) violations.

To View This Article:

Login

Subscribe To Devices & Diagnostics Letter

Buy This Article Now

Add this article to your cart for $120.00